These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 26646536)

  • 1. A review of adverse events linked to dopamine agonists in the treatment of Parkinson's disease.
    Ceravolo R; Rossi C; Del Prete E; Bonuccelli U
    Expert Opin Drug Saf; 2016; 15(2):181-98. PubMed ID: 26646536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The safety of dopamine agonists in the treatment of Parkinson's disease.
    Bonuccelli U; Ceravolo R
    Expert Opin Drug Saf; 2008 Mar; 7(2):111-27. PubMed ID: 18324875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An update on the use of non-ergot dopamine agonists for the treatment of Parkinson's disease.
    Cerri S; Blandini F
    Expert Opin Pharmacother; 2020 Dec; 21(18):2279-2291. PubMed ID: 32804544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of dopamine agonists in early Parkinson's disease.
    Watts RL
    Neurology; 1997 Jul; 49(1 Suppl 1):S34-48. PubMed ID: 9222273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The role of dopaminagonists in the treatment of Parkinson's disease].
    Ransmayr G
    Praxis (Bern 1994); 2005 Oct; 94(42):1633-8. PubMed ID: 16277084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.
    Talati R; Baker WL; Patel AA; Reinhart K; Coleman CI
    Int J Clin Pract; 2009 Apr; 63(4):613-23. PubMed ID: 19222614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Use of pronoran (piribedil) in Parkinson's disease: the results of a multicenter study].
    Fedorova NV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2003; 103(11):21-4. PubMed ID: 14681961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuncts to levodopa therapy: dopamine agonists.
    Poewe W
    Neurology; 1998 Jun; 50(6 Suppl 6):S23-6; discussion S44-8. PubMed ID: 9633683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dopamine agonists in the treatment of Parkinson's disease.
    Bonuccelli U; Pavese N
    Expert Rev Neurother; 2006 Jan; 6(1):81-9. PubMed ID: 16466315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Rasagiline in monotherapy in patients with early stages of Parkinson's disease and in combined and adjunct therapy to levodopa with moderate and advanced stages].
    Pagonabarraga J; Rodríguez-Oroz MC
    Rev Neurol; 2013 Jan; 56(1):25-34. PubMed ID: 23250679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
    Kondo T
    J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing dopamine agonists in Parkinson's disease.
    Bonuccelli U
    Curr Opin Neurol; 2003 Dec; 16 Suppl 1():S13-9. PubMed ID: 15180133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Parkinson's disease should begin with a dopamine agonist.
    Montastruc JL
    Mov Disord; 2000 Mar; 15(2):361-2. PubMed ID: 10752600
    [No Abstract]   [Full Text] [Related]  

  • 14. Switching from ergot to nonergot dopamine agonists in Parkinson's disease: a clinical series and five-drug dose conversion table.
    Grosset K; Needleman F; Macphee G; Grosset D
    Mov Disord; 2004 Nov; 19(11):1370-4. PubMed ID: 15389984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ropinirole in the symptomatic treatment of Parkinson's disease.
    Brooks DJ; Torjanski N; Burn DJ
    J Neural Transm Suppl; 1995; 45():231-8. PubMed ID: 8748630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The initial treatment of Parkinson's disease.
    Factor SA
    Mov Disord; 2000 Mar; 15(2):360-1. PubMed ID: 10752599
    [No Abstract]   [Full Text] [Related]  

  • 17. Rationale for use of dopamine agonists in Parkinson's disease: review of ergot derivatives.
    Blanchet PJ
    Can J Neurol Sci; 1999 Aug; 26 Suppl 2():S21-6. PubMed ID: 10451756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Parkinson disease. Directed use of modern therapy].
    Möller JC; Wächter T; Oertel WH
    MMW Fortschr Med; 2001 May; 143 Suppl 2():45-50. PubMed ID: 11434257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A reassessment of risks and benefits of dopamine agonists in Parkinson's disease.
    Antonini A; Tolosa E; Mizuno Y; Yamamoto M; Poewe WH
    Lancet Neurol; 2009 Oct; 8(10):929-37. PubMed ID: 19709931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drugs for Parkinson's disease.
    Treat Guidel Med Lett; 2013 Nov; 11(135):101-6. PubMed ID: 24165688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.